387 related articles for article (PubMed ID: 33196892)
41. Clinical Significance of PD-L1 Protein Expression in Surgically Resected Primary Lung Adenocarcinoma.
Takada K; Okamoto T; Shoji F; Shimokawa M; Akamine T; Takamori S; Katsura M; Suzuki Y; Fujishita T; Toyokawa G; Morodomi Y; Okano S; Oda Y; Maehara Y
J Thorac Oncol; 2016 Nov; 11(11):1879-1890. PubMed ID: 27346415
[TBL] [Abstract][Full Text] [Related]
42. Changes in programmed death ligand 1 expression in non-small cell lung cancer patients who received anticancer treatments.
Omori S; Kenmotsu H; Abe M; Watanabe R; Sugino T; Kobayashi H; Nakashima K; Wakuda K; Ono A; Taira T; Naito T; Murakami H; Ohde Y; Endo M; Akiyama Y; Nakajima T; Takahashi T
Int J Clin Oncol; 2018 Dec; 23(6):1052-1059. PubMed ID: 29948239
[TBL] [Abstract][Full Text] [Related]
43. Distribution and concordance of PD-L1 expression by routine 22C3 assays in East-Asian patients with non-small cell lung cancer.
Fu F; Deng C; Sun W; Zheng Q; Jin Y; Li Y; Zhang Y; Chen H
Respir Res; 2022 Nov; 23(1):302. PubMed ID: 36335353
[TBL] [Abstract][Full Text] [Related]
44. Association of PD-L1 expression and PD-L1 gene polymorphism with poor prognosis in lung adenocarcinoma and squamous cell carcinoma.
Yeo MK; Choi SY; Seong IO; Suh KS; Kim JM; Kim KH
Hum Pathol; 2017 Oct; 68():103-111. PubMed ID: 28851662
[TBL] [Abstract][Full Text] [Related]
45. PD-L1 expression and its relationship with oncogenic drivers in non-small cell lung cancer (NSCLC).
Jiang L; Su X; Zhang T; Yin X; Zhang M; Fu H; Han H; Sun Y; Dong L; Qian J; Xu Y; Fu X; Gavine PR; Zhou Y; Tian K; Huang J; Shen D; Jiang H; Yao Y; Han B; Gu Y
Oncotarget; 2017 Apr; 8(16):26845-26857. PubMed ID: 28460468
[TBL] [Abstract][Full Text] [Related]
46. Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall-cell lung cancer.
Azuma K; Ota K; Kawahara A; Hattori S; Iwama E; Harada T; Matsumoto K; Takayama K; Takamori S; Kage M; Hoshino T; Nakanishi Y; Okamoto I
Ann Oncol; 2014 Oct; 25(10):1935-1940. PubMed ID: 25009014
[TBL] [Abstract][Full Text] [Related]
47. A retrospective analysis of eleven gene mutations, PD-L1 expression and clinicopathological characteristics in non-small cell lung cancer patients.
Liu Y; Wu A; Li X; Wang S; Fang S; Mo Y
Asian J Surg; 2022 Jan; 45(1):367-375. PubMed ID: 34325991
[TBL] [Abstract][Full Text] [Related]
48. PD-L1 expression and its clinicopathologic and genomic correlation in the non-small cell lung carcinoma patients: An Indian perspective.
Jain E; Sharma S; Aggarwal A; Bhardwaj N; Dewan A; Kumar A; Jain D; Bhattacharya M; Saurav GK; Kini L; Mohanty SK
Pathol Res Pract; 2021 Dec; 228():153497. PubMed ID: 34053784
[TBL] [Abstract][Full Text] [Related]
49. [Correlation between the Expression of PD-L1 in Pleural Effusion of Lung Adenocarcinoma and the Clinicopathological Features and Molecular Changes].
Ma H; Jia J; Guo H; Zhao H; Wang C; Zhao L; Sun Y; Li W; Zhang Z
Zhongguo Fei Ai Za Zhi; 2020 Mar; 23(3):150-155. PubMed ID: 32209183
[TBL] [Abstract][Full Text] [Related]
50. Predictive value of oncogenic driver subtype, programmed death-1 ligand (PD-L1) score, and smoking status on the efficacy of PD-1/PD-L1 inhibitors in patients with oncogene-driven non-small cell lung cancer.
Ng TL; Liu Y; Dimou A; Patil T; Aisner DL; Dong Z; Jiang T; Su C; Wu C; Ren S; Zhou C; Camidge DR
Cancer; 2019 Apr; 125(7):1038-1049. PubMed ID: 30548240
[TBL] [Abstract][Full Text] [Related]
51. Clinical significance of ≥ 50% PD-L1 expression with the SP263 monoclonal antibody in non-small cell lung cancer patients.
Li W; Song P; Guo L; Liu X; Guo C; Ying J; Gao S
Thorac Cancer; 2019 Feb; 10(2):175-182. PubMed ID: 30536734
[TBL] [Abstract][Full Text] [Related]
52. Expression of phosphatase and tensin homolog and programmed cell death ligand 1 in adenosquamous carcinoma of the lung.
Hlaing AM; Furusato B; Udo E; Kitamura Y; Souda M; Masutani M; Fukuoka J
Biochem Biophys Res Commun; 2018 Sep; 503(4):2764-2769. PubMed ID: 30100056
[TBL] [Abstract][Full Text] [Related]
53. Intrinsic and Extrinsic Regulation of PD-L2 Expression in Oncogene-Driven Non-Small Cell Lung Cancer.
Shibahara D; Tanaka K; Iwama E; Kubo N; Ota K; Azuma K; Harada T; Fujita J; Nakanishi Y; Okamoto I
J Thorac Oncol; 2018 Jul; 13(7):926-937. PubMed ID: 29596910
[TBL] [Abstract][Full Text] [Related]
54. Comparison of 22C3 PD-L1 Expression between Surgically Resected Specimens and Paired Tissue Microarrays in Non-Small Cell Lung Cancer.
Li C; Huang C; Mok TS; Zhuang W; Xu H; Miao Q; Fan X; Zhu W; Huang Y; Lin X; Jiang K; Hu D; Chen X; Huang P; Lin G
J Thorac Oncol; 2017 Oct; 12(10):1536-1543. PubMed ID: 28751245
[TBL] [Abstract][Full Text] [Related]
55. Clinicopathological characteristics and tumor infiltrating immune cells associations of PD-L1 tumor expression in non-small cell lung cancer patients.
Aazzane O; Bakhtaoui FZ; Stitou S; Fellah H; Karkouri M
Tunis Med; 2024 Apr; 102(4):223-228. PubMed ID: 38746962
[TBL] [Abstract][Full Text] [Related]
56. Mutation profile and programmed death ligand 1 status of patients with non-small cell lung cancer diagnosed with "adenocarcinoma" and "non-small cell carcinoma favor adenocarcinoma".
Shigeta N; Yokose T; Murakami S; Isaka T; Shinada K; Yoshioka E; Narita A; Katakura K; Kondo T; Kato T; Nagashima T; Saito H; Ito H
Thorac Cancer; 2024 Feb; 15(6):458-465. PubMed ID: 38197164
[TBL] [Abstract][Full Text] [Related]
57. ALK variants, PD-L1 expression, and their association with outcomes in ALK-positive NSCLC patients.
Chang GC; Yang TY; Chen KC; Hsu KH; Huang YH; Su KY; Yu SL; Tseng JS
Sci Rep; 2020 Dec; 10(1):21063. PubMed ID: 33273548
[TBL] [Abstract][Full Text] [Related]
58. Profiling non-small cell lung cancer reveals that PD-L1 is associated with wild type EGFR and vascular invasion, and immunohistochemistry quantification of PD-L1 correlates weakly with RT-qPCR.
Alwithenani A; Bethune D; Castonguay M; Drucker A; Flowerdew G; Forsythe M; French D; Fris J; Greer W; Henteleff H; MacNeil M; Marignani P; Morzycki W; Plourde M; Snow S; Marcato P; Xu Z
PLoS One; 2021; 16(5):e0251080. PubMed ID: 33956842
[TBL] [Abstract][Full Text] [Related]
59. Investigation on the survival implications of PD-L1 expression status in ALK- rearranged advanced non-small cell lung cancer treated with first-line crizotinib.
Zhou Y; Song L; Xu Q; Zeng L; Jiang W; Yang N; Zhang Y
Lung Cancer; 2022 May; 167():58-64. PubMed ID: 35405360
[TBL] [Abstract][Full Text] [Related]
60. Various impacts of driver mutations on the PD-L1 expression of NSCLC.
Chu CH; Huang YH; Lee PH; Hsu KH; Chen KC; Su KY; Yu SL; Tseng JS; Yang TY; Chang GC
PLoS One; 2022; 17(8):e0273207. PubMed ID: 35980949
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]